Crystal structure of chromo barrel domain of RBBP1

Ming Lei^{a, b#}, Yue Feng^{b#}, Mengqi Zhou^a, Yuan Yang^c, Peter Loppnau^b, Yanjun Li^b, Yi Yang^{d*} and Yanli Liu^{a, b*}

^a Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan 430079, PR China

^b Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada

^c Graduate school, Wuhan Sports University, Wuhan 430079, PR China

^d College of Health Science, Wuhan Sports University, Wuhan 430079, PR China

[#] These authors contributed equally to this work

* To whom correspondence should be addressed: yangyi999999@yahoo.com and yanliliu@mail.ccnu.edu.cn

Abstract

RBBP1 is a retinoblastoma protein (pRb) binding protein acting as a repressor of gene transcription. RBBP1 is a multidomain protein including a chromo barrel domain, and its chromo barrel domain has been reported to recognize histone H4K20me3 weakly, and this binding is enhanced by the simultaneous binding of DNA. However, the molecular basis of this DNA-mediated histone binding by the chromo barrel domain of RBBP1 is unclear. Here we attempted to co-crystallize the chromo barrel domain of RBBP1 with either a histone H4K20me3 peptide alone or with both a histone H4K20me3 peptide and DNA, but only solved the peptide/DNA unbound crystal structure. Our structural analysis indicates that RBBP1 could interact with histone H4K20me3 similar to other histone binding chromo barrel domains, and the surface charge representation analysis of the chromo barrel domain of RBBP1 suggests that the chromo barrel domain of RBBP1 does not have a typical DNA binding surface, indicating that it might not bind to DNA. Consistently, our ITC assays also showed that DNA does not significantly enhance the histone binding ability of the chromo barrel domain of RBBP1.

Keywords: RBBP1, chromo barrel domain, histone methylation, nucleosome, DNA

Introduction

RBBP1 (retinoblastoma-binding protein 1), also known as ARID4A, was first cloned from human complementary DNA expression library, which was found by using retinoblastoma protein (pRb, a tumor suppressor protein) as a bait to search for the potential interaction proteins of pRb [1]. As a corepressor of pRb, RBBP1 binds to the pocket domain of pRb and participates in the suppression of E2F (a transcription factor)-mediated transcription via both histone deacetylase (HDAC)-dependent and -independent repression activities [2,3]. RBBP1 functions as a tumor and leukemia suppressor and interacts with the mSin3A complex to repress gene transcription [4,5,6]. Further study also suggests that RBBP1 participates in regulation of epigenetic modification such as histone methylation as discovered in Prader-Willi/Angelman syndrome and leukemia [6,7].

RBBP1 is a multidomain protein, containing a double Tudor domain, a PWWP domain, an ARID domain, a chromo barrel domain and a R2 domain from the N terminus to the C terminus [8]. The ARID domain is reported to bind to DNA with AT-rich sequences, however the ARID domain of RBBP1 showed no DNA sequence preference [9]. Tudor domain, PWWP domain and chromo barrel domain are members of Royal family domains, which are reported to bind to the methylated histone tails [10,11,12,13]. However, the double Tudor domain of RBBP1, which forms an hybrid Tudor domain does not bind to methylated histone but interacts with DNA without sequential specificity [14]. The PWWP domain in general interacts with chromatin by synergistically binding to both histone and DNA [15]. However, the function of PWWP domain of RBBP1 is not reported yet. The chromo barrel domain of RBBP1 binds to histone H4K20me3 peptide at a millimolar affinity, and this binding is reported to be reinforced by the interaction of chromo barrel domain with DNA [8]. However, the molecular mechanisms of these interactions are still unclear.

To better understand the interactions between the chromo barrel domain of RBBP1 and histone H4K20me3 peptide and DNA, we aimed to analyze these interactions by quantitative binding assays and crystallographic analysis. In this study, we tried to analyze the interaction between the chromo barrel domain of RBBP1 and

histone H4K20me3 peptide with or without DNA by quantitative isothermal titration calorimetry (ITC) binding assays, however the histone binding is too weak to be measured reliably and the addition of DNA does not enhance the histone binding. Next, we attempted to co-crystallize the chromo barrel domain of RBBP1 with both histone H4K20me3 peptide and DNA or with histone H4K20me3 peptide only, and solved the peptide/DNA unbound structure only. Further structural study indicates that chromo domain of RBBP1 could interact with H4K20me3 peptide similar to other chromo barrel domains, while it may not bind to DNA since it does not have a continuous positively charged surface like other DNA binding proteins.

Results and discussion

Interaction between chromo barrel domain of RBBP1 and histone H4K20me3 peptide not detected by ITC with or without DNA

According to a previous report, the chromo barrel domain of RBBP1 binds to H4K20me3 peptide and this interaction is strengthened by adding DNA [8]. Our isothermal calorimetry (ITC) assays failed to detect such binding to the H4K20me3 peptide with or without DNA (Fig. 1A and 1B). The reported binding affinity of the chromo barrel domain of RBBP1 to H4K20me3 is 6 mM [8], which might fall below our ITC assays' limits of detection. However, we also could not observe higher binding affinity (0.4 mM) by adding DNA to the protein of the chromo barrel domain of RBBP1 before detecting its binding to histone H4K20me3 by ITC.

Crystal structure of chromo barrel domain of RBBP1

To gain structural insight into the interaction between the chromo barrel domain of RBBP1 and its partners, we tried to crystalize it with its partners and solved the chromo barrel domain structure only (Table 1 and Fig. 2).

There is one chromo barrel domain molecule in the asymmetrical unit in the RBBP1 crystal model. The overall structure of the RBBP1 chromo barrel domain is in accordance with the previously reported NMR structure (Fig. 3A) [8]. Briefly, it contains 5 β strands and 3 short 3_{10} helices (η_1 , η_2 and η_3) with one between the β -strands of β_1 and β_2 , one between the β -strands of β_3 and β_4 , the other between the β -strands of β_4 and β_5 (Fig. 2A). The potential methylated lysine binding cage is made up by five aromatic residues, Tyr583, Tyr592, Tyr612, Trp615 and Tyr619, which side chains are oriented perpendicularly to each other to form five sides of a cube (Fig. 2A). The mutagenesis analyses have confirmed that residues Tyr592, Tyr612, Trp615 and Tyr619 play an important role in the H4K20me3 peptide recognition, however, Tyr583 is independent [8]. However, the electrostatic potential surface analysis indicates that there is no significant positively charged protein surface in the RBBP1 chromo barrel domain, which is consistent with its predicted theoretical pI value 5.76 (Fig. 2B). The protein surface of the RBBP1 chromo domain

is different from other DNA binding proteins' surface, such as the CXXC domains [16,17], therefore it may not bind to DNA.

Structure comparison of chromo barrel domain of TIP60 to other chromo barrel domain

The crystal and NMR structure of the chromo barrel domain of RBBP1 are almost the same, except two more short 3_{10} helices ($\eta 1$ and $\eta 2$) in the crystal structure (Fig. 3A). Comparison to the ScEaf3 chromo barrel domain structure indicates that the C terminal long α helix is absent in the RBBP1 protein. The aromatic cage residues of RBBP1 are superimposed very well with those of the ScEaf3 protein, indicating that RBBP1 may recognize histone peptide in the same way as ScEaf3 (Fig. 3B).

In conclusion, our quantitative ITC binding assays reveal that the interaction between chromo barrel domain of RBBP1 and its partner is quite weak to be not reliably measured by regular ITC assay. Our crystal structure provides the molecular basis of the recognition of histone peptide by RBBP1 chromo barrel domain and indicates that it may not bind to DNA since it does not have a continuous positively charged surface like other DNA binding proteins, such as the CXXC domains.

Materials and methods

Protein expression and purification

The chromo barrel domain of RBBP1 (residues 568-635) was subcloned into a modified pET28-MHL vector. The encoded N-terminal His-tagged fusion protein was overexpressed in *Escherichia coli* BL21 (DE3) Codon plus RIL (Stratagene) cells at 15 °C and purified by affinity chromatography on Ni-nitrilotriacetate resin (Qiagen), followed by TEV protease treatment to remove the tag. Protein was further purified by Superdex75 gel-filtration (GE Healthcare, Piscataway, NJ). For crystallization experiments, purified protein was concentrated to 7.6 mg/mL in a buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl and 1 mM DTT. The molecular weight of the purified protein was determined by mass spectrometry.

Isothermal Titration Calorimetry (ITC)

The histone H4K20me3 peptide was synthesized by Peptide 2.0 Inc. For ITC measurements, the concentrated protein was diluted in 20 mM Tris, pH 7.5, and 150 mM NaCl. Likewise, the lyophilized peptide was dissolved in the same buffer and pH was adjusted by adding NaOH. Peptide concentration was estimated from the mass of lyophilized material. The two complementary ssDNA with sequences of 5'-ctcaggtcaaaggtcacg-3', 3'-agtccagttccagtgc-5' (according to previous study [8]) were dissolved in the same buffer and pH was adjusted by adding NaOH. Then the two ssDNA were annealed to dsDNA by PCR instrument by decreasing 5 °C/min from 95 °C to 25 °C. All ITC measurements were performed at 25 °C, using a VP-ITC microcalorimeter (GE Healthcare). Protein with a concentration of 100 µM or pre-mixed with DNA at a 1:1 molar ratio was placed in the cell chamber, and the peptide with a concentration of 2 mM in syringe was injected in 25 successive injections with a spacing of 180 s and a reference power of 13 µcal/s. Control experiments were performed under identical conditions to determine the heat signals that arise from injection of the peptides into the buffer. Data were fitted using the single-site binding model within the Origin software package (MicroCal, Inc.).

Crystallization

Purified RBBP1 (7.6 mg/mL) was mixed with dsDNA and H4K20me3 peptide at 1:1.2:5 molar ratio, and crystallized using the sitting drop vapor diffusion method at 18 °C by mixing 0.5 µL of the protein with 0.5 µL of the reservoir solution. The crystals were obtained in a buffer containing 25% PEG 3350, 0.2 M magnesium chloride, 0.1 M Hepes, pH 7.5.

Data collection and structure determination

Diffraction data were collected on a copper rotating anode x-ray source under sample cooling to 100 K. Diffraction images were processed with XDS [18] and symmetry-related intensities merged with AIMLESS [19]. The structure was solved by molecular replacement with PHASER [20] software and coordinates from PDB entry 2LCC [8]. The model was automatically rebuilt with ARP/wARP [21] and interactively modified in COOT [22]. REFMAC [23] and AUTOBUSTER [24] were used for restrained model refinement. PHENIX [25] programs were used for geometry validation [26] and calculation of model statistics. Additional information on crystallographic experiments and models is listed in Table 1.

Accession number

Coordinates and structure factor amplitudes of chromo barrel domains of RBBP1 were deposited in the PDB with accession code 6BPH.

Acknowledgements

We would like to thank Wolfram Tempel for data collection and structure determination. Results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. Argonne is operated by UChicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357. This study was supported by the National Natural Science Foundation of China [grant number 31500613] and Hubei Chenguang Talented Youth Development Foundation. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

Reference

- [1] D. Defeo-Jones, P.S. Huang, R.E. Jones, K.M. Haskell, G.A. Vuocolo, M.G. Hanobik, H.E. Huber, A. Oliff, Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product, *Nature* 352 (1991) 251-254.
- [2] A. Lai, J.M. Lee, W.M. Yang, J.A. DeCaprio, W.G. Kaelin, Jr., E. Seto, P.E. Branton, RBP1 recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins, *Mol Cell Biol* 19 (1999) 6632-6641.
- [3] A. Lai, R.C. Marcellus, H.B. Corbeil, P.E. Branton, RBP1 induces growth arrest by repression of E2F-dependent transcription, *Oncogene* 18 (1999) 2091-2100.
- [4] A. Lai, B.K. Kennedy, D.A. Barbie, N.R. Bertos, X.J. Yang, M.C. Theberge, S.C. Tsai, E. Seto, Y. Zhang, A. Kuzmichev, W.S. Lane, D. Reinberg, E. Harlow, P.E. Branton, RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest, *Mol Cell Biol* 21 (2001) 2918-2932.
- [5] T.C. Fleischer, U.J. Yun, D.E. Ayer, Identification and characterization of three new components of the mSin3A corepressor complex, *Mol Cell Biol* 23 (2003) 3456-3467.
- [6] M.Y. Wu, K.W. Eldin, A.L. Beaudet, Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes, *J Natl Cancer Inst* 100 (2008) 1247-1259.
- [7] M.Y. Wu, T.F. Tsai, A.L. Beaudet, Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain, *Genes Dev* 20 (2006) 2859-2870.
- [8] W.B. Gong, T. Zhou, J.J. Mo, S. Perrett, J.F. Wang, Y.G. Feng, Structural Insight into Recognition of Methylated Histone Tails by Retinoblastoma-binding Protein 1, *Journal of Biological Chemistry* 287 (2012) 8531-8540.
- [9] A. Patsialou, D. Wilsker, E. Moran, DNA-binding properties of ARID family proteins, *Nucleic Acids Research* 33 (2005) 66-80.
- [10] S. Maurer-Stroh, N.J. Dickens, L. Hughes-Davies, T. Kouzarides, F. Eisenhaber, C.P. Ponting, The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains, *Trends in Biochemical Sciences* 28 (2003) 69-74.
- [11] M. Adams-Cioaba, J. Min, Structure and function of histone methylation binding proteins, *Biochemistry & Cell Biology* 87 (2009) 93-105.
- [12] D.J. Patel, Z. Wang, Readout of epigenetic modifications, *Annual Review of Biochemistry* 82 (2013) 81-118.
- [13] Y. Liu, J. Min, Structure and function of histone methylation-binding proteins in plants, *Biochemical Journal* 473 (2016) 1663-1680.
- [14] W. Gong, J. Wang, S. Perrett, Y. Feng, Retinoblastoma-binding protein 1 has an interdigitated double Tudor domain with DNA binding activity, *Journal of Biological Chemistry* 289 (2014) 4882-4895.
- [15] Q. Su, J. Min, Structure and function of the nucleosome-binding PWWP domain, *Trends in Biochemical Sciences* 39 (2014) 536-547.
- [16] C. Xu, C. Bian, R. Lam, A. Dong, J. Min, The structural basis for selective binding of non-methylated CpG islands by the CFP1 CXXC domain, *Nature Communications* 2 (2011) 227.
- [17] C. Xu, K. Liu, M. Lei, A. Yang, Y. Li, T.R. Hughes, J. Min, DNA Sequence Recognition of Human CXXC Domains and Their Structural Determinants, *Structure*. (2018) 85-95.
- [18] W. Kabsch, Xds, *Acta Crystallographica Section D Biological Crystallography* 66 (2010) 125-132.

- [19] P.R. Evans, G.N. Murshudov, How good are my data and what is the resolution?, *Acta Crystallographica Section D Biological Crystallography* 69 (2013) 1204-1214.
- [20] A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, R.J. Read, Phaser crystallographic software, *Journal of Applied Crystallography* 40 (2007) 658-674.
- [21] G. Langer, S.X. Cohen, V.S. Lamzin, A. Perrakis, Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7, *Nature Protocols* 3 (2008) 1171-1179.
- [22] P. Emsley, B. Lohkamp, W.G. Scott, K. Cowtan, Features and development of Coot, *Acta Crystallographica Section D Biological Crystallography* 66 (2010) 486-501.
- [23] G.N. Murshudov, P. Skubák, A.A. Lebedev, N.S. Pannu, R.A. Steiner, R.A. Nicholls, M.D. Winn, F. Long, A.A. Vagin, REFMAC5 for the refinement of macromolecular crystal structures, *Acta Crystallographica Section D Biological Crystallography* 67 (2011) 355-367.
- [24] B. G., B. E., B. M., F. C., K. P., P. W., R. P., S. A., S. O.S., V. C., W. T.O., BUSTER, Cambridge, United Kingdom: Global Phasing Ltd. 3 (2017) 1171-1179.
- [25] P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.-W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger, P.H. Zwart, PHENIX: a comprehensive Python-based system for macromolecular structure solution, *Acta Crystallographica Section D Biological Crystallography* 66 (2010) 213-221.
- [26] V.B. Chen, J.J. Headd, D.A. Keedy, R.M. Immormino, G.J. Kapral, L.W. Murray, J.S. Richardson, D.C. Richardson, MolProbity: all-atom structure validation for macromolecular crystallography, *Acta Crystallographica* 66 (2010) 12-21.
- [27] C.I. Bayly, P. Cieplak, W. Cornell, P.A. Kollman, A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model, *The Journal of Physical Chemistry* 97 (1993) 10269-10280.

Figure legends

Figure 1 Interaction between chromo barrel domain of RBBP1 and histone H4K20me3 peptide not detected by ITC with or without DNA

(A and B) ITC binding curves of histone H4K20me3 peptide to chromo barrel domain of RBBP1 without (A) or with DNA (B).

Figure 2 Structure of chromo barrel domain of RBBP1.

(A) Overall structure of chromo barrel domain of RBBP1. The secondary structure elements are shown as cartoons and colored cyan, with the potential cage forming residues shown as sticks. (B) Electrostatic potential surface representation of chromo barrel domain of RBBP1 (isocontour values of ± 78.2 kT/e). Negative and positive potentials are depicted in red and blue, respectively. The potential binding cage resign for the methylated lysine is shown by black circle. Structure figures were generated by using PyMOL (<http://pymol.sourceforge.net>). Electrostatic potential surface representations were calculated with PyMOL's built-in *protein contact potential* function [27].

Figure 3 Structural comparison of chromo barrel domains.

(A) Superimposition of chromo barrel domain of RBBP1 crystal structure (PDB code: 6BPH, cyan, this work) and NMR structure (PDB code: 2LCC, blue). (B) Superimposition of chromo barrel domain of RBBP1 (PDB code: 6BPH, cyan, this work) and ScEaf3 (PDB code: 2K3Y, salmon).

Table 1 Data collection and refinement statistics

PDB entry	6BPH
Data Processing	
Space group	P43212
Cell dimensions a, c [Å]	41.5, 81.4
Resolution (high resolution shell) [Å]	36.97–1.80 (1.84-1.80)
Rmerge	0.072 (1.077)
Mean(I/σ)	26.2 (3.3)
Completeness [%]	99.6 (98.8)
Multiplicity	13.1 (13.3)
Model Refinement	
Resolution [Å]	36.90-1.85
Reflections work / free	6196 / 312
R-value	0.206 / 0.226
Number of atoms: protein / water / unassigned (UNX)	537 / 24 / 17
Mean B-factor [Å ²] protein / water	30.8 / 37.7
RMSD from ideal values: bonds [Å] / angles [°] (PHENIX.MOLPROBITY)	0.013 / 1.5

Figure 1

A

B

RBBP1 Crystal (6BPH)

RBBP1 Crystal (6BPH)

Figure 2

A

RBBP1 crystal (6BPH)-NMR (2LCC)

B

RBBP1 (6BPH)-ScEaf3 (2K3Y)